Skip to main content
All lobbying filings

PHLOW CORPORATION

Lobbying for PHLOW CORPORATION

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$390,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Virginia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3

FY27 Labor, Health and Human Services, Education, and Related Agencies Appropriations (H.R.9260); FY27 Department of Defense Appropriations (H.R.9495)

Administrations activities related to pharmaceutical supply chain and domestic capacity; Department of Health and Human Services activities related to pharmaceutical supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Administrations activities related to pharmaceutical supply chain and domestic capacity; Department of Health and Human Services activities related to pharmaceutical supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

 Bills named in this filing 6
  • H.R. 9260
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
  • H.R. 9495
    Department of Defense Appropriations Act, 2027
  • S. 1784
    MAPS Act
  • H.R. 4191
    MAPS Act
  • S. 2062
    RAPID Reserve Act
  • H.R. 3966
    Improving Atmospheric River Forecasts Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem